BIOEQUIVALENCE STUDY OF MELOXICAM 15 MG TABLET PRODUCED BY PT MAHAKAM BETA FARMA IN COMPARISON WITH MOBIC (MELOXICAM 15 MG) TABLET MANUFACTURED BY BOEHRINGER INGELHEIM ELLAS AE, KOROPI, GREECE
Tahapan Penelitian : Complete
Sponsor:
PT. Mahakam Beta Farma
Mitra Pelaksana:
No Registry
INA-H64QL3T
Tanggal Input Registry : 02-04-2024
| Tracking Information | |
|---|---|
| Tanggal Antisipasi Studi | 18-11-2023 |
| Outcome Primer | The objective of the present study was to assess the bioequivalence of Meloxicam 15 mg tablet produced by PT Mahakam Beta Farma to Mobic® (Meloxicam 15 mg) tablet manufactured by Boehringer Ingelheim Ellas A.E., Koropi, Greece. |
| Outcome Skunder | |
| Descriptive Information | |
| Judul Penelitian Popular | BIOEQUIVALENCE STUDY OF MELOXICAM 15 MG TABLET PRODUCED BY PT MAHAKAM BETA FARMA IN COMPARISON WITH MOBIC (MELOXICAM 15 MG) TABLET MANUFACTURED BY BOEHRINGER INGELHEIM ELLAS AE, KOROPI, GREECE |
| Judul Penelitian Ilmiah | BIOEQUIVALENCE STUDY OF MELOXICAM 15 MG TABLET PRODUCED BY PT MAHAKAM BETA FARMA IN COMPARISON WITH MOBIC (MELOXICAM 15 MG) TABLET MANUFACTURED BY BOEHRINGER INGELHEIM ELLAS AE, KOROPI, GREECE |
| Jenis Penelitian | Observational |
| Intervensi | |
| Jumlah Subyek Penelitian | 15 |
| Recruitment Information | |
| Eligibility Criteria | Inclusion Criteria: - Willing to sign the informed consent, - Age 18 – 55 years, - Body mass index between 18 – 25 kg/m2, - Normotensive (systolic blood pressure 100 – 120 mmHg, diastolic blood pressure 60-80 mmHg), heart rate 60 – 90 beats per minute. - Healthy male (healthy criteria is determined by normal values or if outside the normal range of values but no clinically significant effects based on doctors' justification on the result of laboratory test include routine hematology, liver function, renal function, blood sugar and urinalysis; history of disease, and physical examination),Exclusion Criteria: - Contraindicated and/or has history of hypersensitivity to Meloxicam or related drug, - With history or present medical condition which might significantly influence the pharmacokinetics of the study drug, e.g. chronic gastrointestinal disease, diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or cardiovascular disease, - Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver function test (ASL, ALT, alkaline phosphatase, total bilirubin, direct bilirubin ≥ 1.5 ULN), renal function test (serum creatinine concentration > 1.4 mg/dL and ureum ≥ 1.5 ULN), etc., - Clinically significant hematology abnormalities, - Show abnormal result or not within the acceptance range (clinically significant effect based on doctor’s justification) in the electrocardiography (ECG) test result, - Using any medication (prescription or non-prescription drug, food supplement, herbal medicine) within 7 days prior to the dosing day, - Participated in any clinical study within 3 months prior the study, - Donated or lost 300 mL (or more) of blood within 3 months prior the study, - Smoke more than 9 sticks of cigarettes a day, - Have any bleeding or coagulation disorder, - Indicate the positive result on test for HbsAg, Anti-HCV and anti-HIV, - With the history of alcohol and drug abuse - If the study is conducted in Covid-19 pandemic situation, the exclusions criteria below must be applied: a. With history of direct contact with a Covid-19 positive person within last 14 days, b. With history or present sore throat, fever (temperature more than 37oC) or short of breath within last 14 days, c. Positive to Covid-19 antigen rapid test. |
| Administrative Information | |
| Nomor Persetujuan Etik | KET-694/UN2.F1/ETIK/PPM.00.02/2023 |
| Nomor Persetujuan Material Transfer Agreement | Not applicable |
| Nomor Persetujuan Pelaksanaan Uji Klinik | PPUK/PPUB number |
| Other Study ID Numbers | |
| Contact Person | Noviyanto |